Press coverage about Uroplasty (NASDAQ:UPI) has trended somewhat positive on Tuesday, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Uroplasty earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave media stories about the medical device company an impact score of 44.8854482509267 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of UPI stock remained flat at $$1.22 during mid-day trading on Tuesday. Uroplasty has a 12-month low of $1.05 and a 12-month high of $4.05.
TRADEMARK VIOLATION WARNING: “Uroplasty (UPI) Receives Daily News Impact Score of 0.10” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/10/uroplasty-upi-receives-daily-news-impact-score-of-0-10.html.
Cogentix Medical, Inc (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover.
Receive News & Ratings for Uroplasty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty and related companies with MarketBeat.com's FREE daily email newsletter.